research Bimatoprost solution 0·03% topical application to the eyelid margin for the treatment of eyelash hypotrichosis
Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
Search
for
Sort by
Research
210-240 / 1000+ results research Reply to “Regarding the risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases”
research Fractional Resurfacing and Topical Bimatoprost for the Treatment of Laser Induced Postinflammatory Hypopigmentation on the Lower Extremities
The combination therapy improved skin pigmentation.
research Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis
Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research Non-scarring Alopecia in Pemphigus Foliaceus
Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Experiences with Smo antagonist vismodegib for the treatment of locally advanced basal cell carcinoma
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
research Infliximab-Associated Psoriasiform Alopecia
Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research Topikal %1 Pimekrolimus Tedavisine Cevap Veren Bir Alopesi Areata Olgusu
Topical 1% pimecrolimus effectively treated alopecia areata.
research 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research Systemic tofacitinib in paediatric alopecia areata
research Eccema dishidrótico palmoplantar asociado a secukinumab
A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.
research 44180 Influence of Baseline Disease Severity Defined by Investigator’s Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
research BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
research Emerging role of baricitinib in dermatology practice: All we need to know!
Baricitinib effectively treats certain skin conditions but may have serious side effects.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research 574 Comparative analysis of quality of life impact in patients with autoimmune blistering disease
Patients with autoimmune blistering diseases experience a reduced quality of life, with the need for better measurement tools, especially for those with mucous membrane pemphigoid.
research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.